Rania El Botty

1.3k total citations
23 papers, 334 citations indexed

About

Rania El Botty is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Rania El Botty has authored 23 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in Rania El Botty's work include Advanced Breast Cancer Therapies (4 papers), Chromatin Remodeling and Cancer (3 papers) and Cancer Cells and Metastasis (3 papers). Rania El Botty is often cited by papers focused on Advanced Breast Cancer Therapies (4 papers), Chromatin Remodeling and Cancer (3 papers) and Cancer Cells and Metastasis (3 papers). Rania El Botty collaborates with scholars based in France, Syria and United Kingdom. Rania El Botty's co-authors include Elisabetta Marangoni, Ivan Bièche, Sophie Vacher, Sophie Château‐Joubert, Sergio Roman‐Roman, Jean‐Luc Servely, Florence Coussy, Dalila Labiod, Ludmilla de Plater and Franck Assayag and has published in prestigious journals such as Molecular Cell, Biomaterials and Cancer Research.

In The Last Decade

Rania El Botty

21 papers receiving 332 citations

Peers

Rania El Botty
Shazia Irshad United Kingdom
Wen-Ren Wu Taiwan
Marta Popęda Poland
Anthony G. Clementz United States
Adrià Bernat‐Peguera Spain
Qing-Shan Wang China
Gregory C. Stachelek United States
Tim Nichols United States
Albin Rudisch Austria
Lilin Ma China
Shazia Irshad United Kingdom
Rania El Botty
Citations per year, relative to Rania El Botty Rania El Botty (= 1×) peers Shazia Irshad

Countries citing papers authored by Rania El Botty

Since Specialization
Citations

This map shows the geographic impact of Rania El Botty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rania El Botty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rania El Botty more than expected).

Fields of papers citing papers by Rania El Botty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rania El Botty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rania El Botty. The network helps show where Rania El Botty may publish in the future.

Co-authorship network of co-authors of Rania El Botty

This figure shows the co-authorship network connecting the top 25 collaborators of Rania El Botty. A scholar is included among the top collaborators of Rania El Botty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rania El Botty. Rania El Botty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rodrigues-Ferreira, Sylvie, Rania El Botty, Laura Sourd, et al.. (2025). Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers. Cancer Letters. 620. 217665–217665. 1 indexed citations
2.
Reinhold, William C., Elisabetta Marangoni, Fathi Elloumi, et al.. (2025). Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. Cancer Research Communications. 5(2). 375–388. 1 indexed citations
3.
Musiani, Daniele, Hatice Yücel, Rania El Botty, et al.. (2025). Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors. Molecular Cell. 85(6). 1072–1084.e10. 3 indexed citations
4.
5.
Iravani, Marjan, Rania El Botty, John Alexander, et al.. (2023). Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers. Cancer Research. 84(1). 17–25. 6 indexed citations
6.
Botty, Rania El, Sophie Vacher, Adrien Briaux, et al.. (2023). HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers. Molecular Oncology. 17(10). 2017–2028. 5 indexed citations
7.
Passeri, Thibault, Ahmed Dahmani, Julien Masliah‐Planchon, et al.. (2022). In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts. Frontiers in Oncology. 12. 960720–960720. 10 indexed citations
8.
Passeri, Thibault, Ahmed Dahmani, Julien Masliah‐Planchon, et al.. (2022). Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft. Cancers. 14(6). 1486–1486. 17 indexed citations
9.
Passeri, Thibault, Ahmed Dahmani, Julien Masliah‐Planchon, et al.. (2022). Abstract LB567: Dramatic in vivo efficacy of the EZH2-inhibitor tazemetostat in PBRM1-mutated human chordoma xenograft. Cancer Research. 82(12_Supplement). LB567–LB567. 1 indexed citations
10.
Jacquemetton, Julien, Loay Kassem, Coralie Poulard, et al.. (2021). Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant. Breast Cancer Research. 23(1). 57–57. 12 indexed citations
11.
Coussy, Florence, Rania El Botty, Laetitia Fuhrmann, et al.. (2020). Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. Journal of Hematology & Oncology. 13(1). 13–13. 43 indexed citations
12.
Han, Weijing, Rania El Botty, Élodie Montaudon, et al.. (2020). In vitro bone metastasis dwelling in a 3D bioengineered niche. Biomaterials. 269. 120624–120624. 25 indexed citations
13.
Cacheux, Wulfran, Astrid Lièvre, Sophie Richon, et al.. (2019). Interaction between IGF2‐PI3K axis and cancer‐associated‐fibroblasts promotes anal squamous carcinogenesis. International Journal of Cancer. 145(7). 1852–1859. 20 indexed citations
14.
Némati, Fariba, et al.. (2019). Improvement of the anti-proliferative activity of the peptide ERα17p in MCF-7 breast cancer cells using nanodiamonds. Annales Pharmaceutiques Françaises. 77(6). 488–495. 3 indexed citations
15.
Decaudin, Didier, Rania El Botty, Gérald Massonnet, et al.. (2018). Selumetinib-based therapy in uveal melanoma patient-derived xenografts. Oncotarget. 9(31). 21674–21686. 18 indexed citations
16.
Coussy, Florence, François Lallemand, Sophie Vacher, et al.. (2017). Clinical value of R-spondins in triple-negative and metaplastic breast cancers. British Journal of Cancer. 116(12). 1595–1603. 28 indexed citations
17.
Euceda, Leslie R., Deborah K. Hill, Rania El Botty, et al.. (2017). Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts. Journal of Proteome Research. 16(5). 1868–1879. 18 indexed citations
18.
19.
Marangoni, Elisabetta, Dalila Labiod, Sophie Château‐Joubert, et al.. (2015). Abstract 1687: Vandetanib as a potential new treatment for ER negative breast cancers. Cancer Research. 75(15_Supplement). 1687–1687. 4 indexed citations
20.
Cottu, Paul, Ivan Bièche, Franck Assayag, et al.. (2014). Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts. Clinical Cancer Research. 20(16). 4314–4325. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shazia Irshad Breakdown of academic impact, for papers by Wen-Ren Wu Breakdown of academic impact, for papers by Marta Popęda Breakdown of academic impact, for papers by Anthony G. Clementz Breakdown of academic impact, for papers by Adrià Bernat‐Peguera Breakdown of academic impact, for papers by Qing-Shan Wang Breakdown of academic impact, for papers by Gregory C. Stachelek Breakdown of academic impact, for papers by Tim Nichols Breakdown of academic impact, for papers by Albin Rudisch Breakdown of academic impact, for papers by Lilin Ma
Rankless by CCL
2026